These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27789690)

  • 1. DrugCentral: online drug compendium.
    Ursu O; Holmes J; Knockel J; Bologa CG; Yang JJ; Mathias SL; Nelson SJ; Oprea TI
    Nucleic Acids Res; 2017 Jan; 45(D1):D932-D939. PubMed ID: 27789690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DrugCentral 2018: an update.
    Ursu O; Holmes J; Bologa CG; Yang JJ; Mathias SL; Stathias V; Nguyen DT; Schürer S; Oprea T
    Nucleic Acids Res; 2019 Jan; 47(D1):D963-D970. PubMed ID: 30371892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. InContext: curation of medical context for drug indications.
    Moodley K; Rieswijk L; Oprea TI; Dumontier M
    J Biomed Semantics; 2021 Feb; 12(1):2. PubMed ID: 33579375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DrugCentral 2021 supports drug discovery and repositioning.
    Avram S; Bologa CG; Holmes J; Bocci G; Wilson TB; Nguyen DT; Curpan R; Halip L; Bora A; Yang JJ; Knockel J; Sirimulla S; Ursu O; Oprea TI
    Nucleic Acids Res; 2021 Jan; 49(D1):D1160-D1169. PubMed ID: 33151287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring DrugCentral: from molecular structures to clinical effects.
    Halip L; Avram S; Curpan R; Borota A; Bora A; Bologa C; Oprea TI
    J Comput Aided Mol Des; 2023 Dec; 37(12):681-694. PubMed ID: 37707619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.
    Bharate SS
    Drug Discov Today; 2021 Feb; 26(2):384-398. PubMed ID: 33221522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SuperDRUG2: a one stop resource for approved/marketed drugs.
    Siramshetty VB; Eckert OA; Gohlke BO; Goede A; Chen Q; Devarakonda P; Preissner S; Preissner R
    Nucleic Acids Res; 2018 Jan; 46(D1):D1137-D1143. PubMed ID: 29140469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DrugCentral 2023 extends human clinical data and integrates veterinary drugs.
    Avram S; Wilson TB; Curpan R; Halip L; Borota A; Bora A; Bologa CG; Holmes J; Knockel J; Yang JJ; Oprea TI
    Nucleic Acids Res; 2023 Jan; 51(D1):D1276-D1287. PubMed ID: 36484092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.
    Torre BG; Albericio F
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies.
    Fu C; Jin G; Gao J; Zhu R; Ballesteros-Villagrana E; Wong ST
    Bioinformatics; 2013 Jul; 29(14):1834-6. PubMed ID: 23681121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mining FDA drug labels using an unsupervised learning technique--topic modeling.
    Bisgin H; Liu Z; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs of 1998.
    Hussar DA
    J Am Pharm Assoc (Wash); 1999; 39(2):151-206; quiz 289-92. PubMed ID: 10079651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil.
    Barreto RB; Izidoro AM; Miranda MHF
    Curr Oncol; 2024 Aug; 31(8):4443-4454. PubMed ID: 39195315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.